Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

NCT01049035 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study was to evaluate the optimal vaccination schedule for a Quadrivalent Meningococcal Polysaccharide (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (MenACYW Conjugate vaccine) in order to provide an effective protein conjugate quadrivalent meningococcal vaccine in the population with the highest incidence of disease. Objectives: * To describe the safety profile of MenACYW Conjugate vaccine administered at 5 different schedules and concomitantly with routine pediatric vaccinations. * To describe the immunogenicity profile of MenACYW Conjugate vaccine administered at 5 different schedules and concomitantly with routine pediatric vaccinations. * To describe the immunogenicity profiles of selected licensed pediatric vaccines (Pentacel, Prevnar, M-M-RII, and Varivax) when administered either concomitantly with or without MenACYW Conjugate vaccine.

Interventions

  • BIOLOGICAL Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate
  • BIOLOGICAL Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)
  • BIOLOGICAL M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live
  • BIOLOGICAL Varicella Virus Vaccine Live
  • BIOLOGICAL Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

Study Locations (20)

Kentucky

  • — Bardstown
  • — Crestview Hills
  • — Louisville
  • — Louisville

Alabama

  • — Birmingham
  • — Tuscaloosa

Arkansas

  • — Jonesboro
  • — Little Rock

California

  • — Fountain Valley
  • — Huntington Beach

Georgia

  • — Marietta
  • — Woodstock

Louisiana

  • — Bossier City

North Carolina

  • — Clyde

Ohio

  • — Cleveland

Trial Details

FieldValue
Enrollment Target 580 participants
Start Date 2009-12-16
Est. Completion 2012-02-13
Phase Phase 2

Sponsor

Sanofi Pasteur, a Sanofi Company

43 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01049035

The ClinicalTrials.gov registry entry for NCT01049035 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 580 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 43 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Meningitis appearing as the primary indexed condition, and to 5 interventions — of which Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01049035 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Kentucky, Alabama, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01049035 about?

NCT01049035 is a clinical study titled "A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers". The purpose of this study was to evaluate the optimal vaccination schedule for a Quadrivalent Meningococcal Polysaccharide (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (MenACYW Conjugate vaccine) in order to provide an effective protein conjugate quadrivalent meningococcal vaccine in the po...

What is the current status of trial NCT01049035?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 580 participants. The study started on 2009-12-16. Estimated completion is 2012-02-13.

What conditions does trial NCT01049035 study?

This clinical trial studies the following conditions: Meningitis, Meningococcal Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01049035?

The interventions under investigation include: Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate (BIOLOGICAL), Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined) (BIOLOGICAL), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live (BIOLOGICAL), Varicella Virus Vaccine Live (BIOLOGICAL), Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01049035?

This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 43 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01049035 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial